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Tumor tissue oxygenation significantly affects the outcome
of radiotherapy. Real-time monitoring of tumor hypoxia is
highly desirable for effective radiotherapy, and is the basis
for improved treatment because hypoxic tumor cells are
more resistant to radiation damage than fully oxygenated
cells. We propose to use Cerenkov imaging to monitor
tumor hypoxia by means of tissue blood oxygenation with-
out the need for any exogenous contrast agent. Using a
rodent hypoxia model, we demonstrate that Cerenkov im-
aging can be used as a noninvasive and noncontact method
to measure tissue blood oxygenation level during radiation
delivery. The data from Cerenkov imaging were validated
using near infrared spectrometry methods. The results
demonstrate the feasibility of using Cerenkov imaging
to monitor tumor hypoxia during therapeutic radiation
delivery. © 2017 Optical Society of America
OCIS codes: (170.3880) Medical and biological imaging; (170.0170)
Medical optics and biotechnology; (170.1470) Blood or tissue con-
stituent monitoring; (170.3890) Medical optics instrumentation;
(170.2655) Functional monitoring and imaging; (170.3660) Light
propagation in tissues.
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It has become increasingly evident that tumor hypoxia is
heterogeneous and dynamic, commonly termed cyclic hypoxia,
and that tumor hypoxia is linked to cancer prognosis in a highly
complex manner [1]. In treating solid tumors, a fundamental
goal is to deliver an optimal dose of radiation to eradicate cancer
cells while minimizing damage to normal tissue. This is made
more challenging because tumor hypoxia increases tumor cell
resistance to radiotherapy [2]. With the availability of technol-
ogies for multidimensional radiation delivery, particularly the
intensity-modulated radiation therapy (IMRT), highly targeted
“dose sculpting” for tumor treatment becomes feasible. However,
as tumor hypoxia can occur with periodicities ranging from mi-
nutes to hours and even to days, the ability of imaging tissue
oxygenation at the time of dose delivery is critically important
for improved outcomes of radiotherapy. A number of methods
for tissue oxygenation imaging have been previously proposed
using well-established medical imaging modalities, e.g., mag-
netic resonance imaging (MRI), positron emission tomography
(PET), and single photon emission computed tomography
(SPECT) [3–5]. However, applications of these methods have
been limited during radiation delivery for a number of reasons:
(1) challenges in system setup because of high equipment costs/
complexity, (2) patient safety concerns due to the use of radio-
active agents, and (3) difficulties in quantitative interpretation
as a result of the indirect and sometimes ambiguous relation-
ship between the contrast mechanisms and the actual oxygena-
tion level. Recently, detection of Cerenkov emission has been
emerging as a promising approach to measure tissue hypoxia.
Cerenkov emission refers to the emission of optical photons
when a charged particle travels at a speed higher than the local
phase velocity of light in the dielectric medium [6]. Cerenkov
emission was observed in biological tissues when radioisotopes
or radiotherapy beams were applied [7–10].
With its far-red and near infrared (NIR) components
(∼650 − 900 nm), Cerenkov emission is well suited for deep-
tissue imaging because of the relatively low absorption and
scattering within this spectral range. Tissue oxygenation state
is directly correlated to the oxy- and deoxy-hemoglobin con-
centrations in blood, i.e., blood oxygen saturation (StO2).
Thanks to the characteristic wavelength-dependent absorption
spectra of oxy- and deoxy-hemoglobin, as well as the noninva-
sive and noncontact capability of optical detection techniques,
imaging of Cerenkov emission becomes a highly promising
solution for deep-tissue StO2 measurement during radiation
delivery. Recently, it has been reported that Cerenkov emission
can be used to measure tissue StO2 via Cerenkov-excited phos-
phorescence [11] and spectral-fitted point-measurement [12].
In this Letter, we report a Cerenkov-based imaging method that
noninvasively measures tissue StO2 during radiation delivery
without using any exogenous contrast agents. This method
measures a parameter (i.e., tissue absorption coefficient) that is
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directly linked to StO2, which determines tissue oxygenation
(pO2). Although highly complex, the absolute relationship be-
tween StO2 and tissue pO2 is deterministic and can be quan-
titatively measured with properly designed calibrations.
Our initial experiment in Cerenkov imaging was performed
on an imaging phantom: excised chicken breast muscles. The
source of high-energy radiation was a clinical linear accelerator
(Novalis Tx, Varian Medical Systems) located at the Duke
University Medical Center. Photon irradiation beams with en-
ergy levels of 6 and 15 MV were used. The radiation doses were
1, 5, 10, 20, 50, 100, and 200 MU (or monitor units) for each
of the two energy levels at a dose rate of 600 MU/min. The
machine was calibrated to deliver 1 cGy/MU at a depth of
1.5 cm (6 MV) or 3 cm (15 MV) to a phantom located 100 cm
away from the source. Images of Cerenkov emission were ac-
quired using a back-illuminated charge-coupled device (CCD)
camera (iKon-M934, Andor Technology), which was equipped
with a general purpose imaging lens (Nikkor 50 mm f ∕1.4,
Nikon). The CCD chip was cooled to −85°C to reduce thermal
noise from the photosensors. Optical acquisition time of the
CCD was 20 s for all measurements. The photon irradiation
beam was delivered vertically from the top. The CCD camera
was positioned approximately 100 cm from the center of field
of view (FOV) at an angle of 45° from the irradiation beam.
The imaging setup was enclosed in a dark imaging chamber
that allowed the irradiation beam to pass without scattering or
other secondary effects. In addition, all the light sources in the
treatment room were turned off or blocked during optical acquis-
ition. We observed that the intensity of Cerenkov emission (in
terms of baseline-corrected CCD count) from the surface of the
imaging phantom follows a linear relationship with respect to the
delivered radiation dose, and that the intensity increases at a faster
rate with respect to the dose at a higher energy (Fig. 1). The dif-
ference in signal intensity between the two energy levels was ap-
proximately 7% under our experimental conditions.
We developed a numeric model to estimate the relationship
between tissue StO2 and Cerenkov emission. The spectrum
of Cerenkov emission extends from ultraviolet (UV) to NIR
following an inverse-square law with respect to emission wave-
length in terms of the photon count [13]. In our numeric
estimation, the spectral range of Cerenkov emission was set
to 650–950 nm, which was jointly limited by tissue attenuation
and the profile of CCD sensitivity. The absorption coefficient
and the reduced scattering coefficient of biological tissue are
wavelength-dependent, which can be described by a set of semi-
empirical equations [14]. Using our numeric model, we found
that the intensity of Cerenkov emission increased almost lin-
early with respect to StO2, which is shown in Fig. 2 as a nor-
malized curve of this dependency. The simulated Cerenkov
intensity changed ∼14% over the entire range of StO2.
Our initial experiment and numerical estimation have lead us
to hypothesize that Cerenkov imaging can measure tissue StO2
level in vivo. To test this hypothesis, we conducted two prelimi-
nary animal experiments. In these experiments, we used Cerenkov
imaging to measure tissue StO2 level of the leg muscles of healthy
adult rats (Sprague Dawley, Charles River Laboratories). Tissue
StO2 was modulated by modifying the O2 fraction of breathing
air for the animals under general anesthesia. The protocols for
animal experiments were approved by the Duke University
Institutional Animal Care and Use Committee (IACUC).
Hair on the thighs was removed using depilatory cream
(Nair) 24 h prior to imaging. The animals were anesthetized
with ketamine/xylazine (60/6 mg/kg initial dose, intraperito-
neal) and supplied with an O2−N2 mixture as breathing air
via a nose cone. Oxygen fraction of the breathing air was gradu-
ally reduced from 100% (i.e., pureO2) to 0% (i.e., pure N2) at
intermediate steps of 50, 25, 20, 15, and 10%. At each step, the
animals breathed the air–N2 mixture for 5–10 min to ensure
the StO2 level was stabilized before imaging. The animals were
euthanized by injection of a lethal dose of Euthasol before
reaching the endpoint.
High-energy photon irradiation beams of 6 MV were deliv-
ered to the right thighs with the same parameters as described
in the phantom experiment: i.e., a radiation dose of 200 MU
with a dose rate of 600 MU/min. The size of the irradiation
beam was 2 × 2 cm. The distribution of radiation dose is highly
uniform in the transverse direction and has a depth-dependent
profile in the longitudinal direction subject to the specific ana-
tomical structures. The variability of irradiation energy and
dose were minimized by the routine quality assurance protocols
for the clinical linear accelerator and were negligible for our
imaging experiments.
For optical acquisition, the same instruments and configu-
rations with similar parameters as detailed in the phantom ex-
periment were also used: i.e., CCD cooled to −85°C, 50 mm
f ∕1.4 lens, 100 cm lens-object distance, 45° imaging angle,
and 25 s acquisition time. A “dark” CCD image was acquired
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Fig. 1. Cerenkov signal intensity versus radiation dose at different
energies in excised chicken breast muscles.
Fig. 2. Estimated dependency of Cerenkov signal on tissue StO2.
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prior to the delivery of radiation to determine the CCD back-
ground signals and the readout noise in Cerenkov image acquis-
itions. The regions of interest (ROIs) for data analysis of all
Cerenkov images were 0.4 × 0.4 cm2.
In the first animal experiment (where N  2), we used a
standard rodent oximeter (MouseOx Plus, Starr Life Sciences)
to validate the measurements from the proposed Cerenkov im-
aging method. This oximeter has a specially designed collar to
affix fiber optics onto the rodent’s neck and measures the
arterial StO2. It was disabled during Cerenkov imaging to avoid
optical interference.
As shown in Fig. 3(a), the photon irradiation beam was
aimed at the right thigh of one of the animals: the bright area
marks the extent of irradiation impinging on the animal, and
the crosshair indicates the FOV center of the irradiation beam.
A raw Cerenkov image of the same animal is shown in Fig. 3(b).
The random background noise in the image was due to scat-
tered radiation in the treatment room, which was eliminated
using a moving-average digital filter during the data processing
stage. The intensity of Cerenkov signals (in terms of the CCD
count) was plotted against the arterial hemoglobin saturation in
Fig. 3(c): using least-squares linear regression, the regression “R”
values of the two data sets were 0.8 and 0.6 for Animals #1 and
#2, respectively; the standard errors of all data points were 9.2–
10.2 counts, which were fairly small (∼4%) compared to their
absolute intensities. The quantum efficiency profile of the
CCD is shown in Fig. 3(d). As the spectral sensitivity profile
of the CCD (∼400 − 900 nm at 50%) overlaps with the NIR
window of ∼650 − 900 nm, the spectrum of acquired Cerenkov
images is predominantly NIR. The results from the first experi-
ment were consistent with our numerical estimation. However, it
is noteworthy that the effects of physiological parameters on
StO2 measurements were difficult to quantify in this experiment:
e.g., arterial StO2 was known to be highly unstable under hy-
poxic conditions; StO2 in the arteries was not perfectly correlated
with that in the leg muscles [15]; and the total blood volume
may have changed due to induced hypoxia.
To address the limitations arising from the uncertain effects
of the above physiological parameters, we designed and per-
formed another experiment, in which all other main experi-
mental conditions remained the same as the first one, except
that the tissue StO2 level was measured locally on the leg
muscles (as opposed to being measured globally at the carotid
arteries). The instrument for local measurement of tissue StO2
was a commercially available visible/NIR spectral oximeter
(Zenalux Biomedical) equipped with a handheld multifiber
optical probe that can be arbitrarily positioned for superficial
measurement.
During the experiment, a circular mark was drawn on the
animal skin to ensure the same sampling locations for both
Cerenkov and validation measurements. The validation mea-
surements were taken immediately before and after each of
the Cerenkov image acquisitions to minimize the effects of
physiological fluctuations. The ROIs for data processing were
centered at the circular marks drawn during the experiment.
Data from the second animal experiment (where N  6)
are shown in Fig. 4. In Fig. 4(a), the mean pixel intensities
within the specified ROIs of Cerenkov images were plotted
against the O2 fraction of breathing air. In Fig. 4(b), tissue
StO2 measured using the Zenalux oximeter at the same ROIs
was plotted similarly.
Both data sets from Cerenkov imaging and NIR oximetry
showed consistent patterns that we have expected: the tissue
StO2 level remained at a constantly high level under hyperoxia
(i.e.,O2 fraction>50%), decreased moderately when the animals
Fig. 3. Animal experiment #1: (a) irradiation beam marked by the
linear accelerator crosshair light superimposed with the animal outline
(white dashed lines; indicating the right leg of animal, pointed upward
toward the 12 o’clock position) and the ROI for Cerenkov signal in-
tensity (red rectangle); (b) Cerenkov image of an animal breathing
100% O2 under 200 MU radiation superimposed with the same ani-
mal outline, ROI, and background (“BG,” green rectangle); (c) in vivo
Cerenkov intensity as a function of hemoglobin saturation in the carotid
artery; and (d) spectral quantum efficiency of the back-illuminated
(“BV”) CCD (adopted from product specifications sheet of Andor
Technology).
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were transitioning from hyperoxia to normoxia (O2 20–50%),
and declined dramatically under hypoxic conditions (O2 < 20%).
Although individual animals may respond differently to the
same oxygen challenge, the data from each individual showed
highly consistent patterns in Cerenkov and Zenalux data. To
further depict the relationship between the two measurements,
the Cerenkov signals were plotted against the tissue StO2 data
obtained from the Zenalux data [Fig. 4(c)]. The Cerenkov sig-
nals were normalized by the average values of individual ani-
mals to reduce the effects of variations of image acquisition
angles and the physiological responses to the changes in O2
fraction of the breathing air. In the averaged data, the Cerenkov
intensity changed ∼5% over the StO2 range of 10–60%, which
is consistent with our numerical estimation in the same range
(∼6% change, Fig. 2). We note that a number of important
system and physiological parameters are needed to quantita-
tively model Cerenkov emission. In practice, however, these
parameters are typically constant within the time frame of
Cerenkov imaging. As a result, quantitative measurement may
be achieved with proper calibration methods, which is a direc-
tion of our future work.
We conclude that Cerenkov imaging can be used as a non-
invasive and noncontact method to measure in vivo tissue StO2
level during the delivery of radiation dose, and that this method
has been qualitatively validated with a rat hypoxia model using
NIR spectrometry. More importantly, no exogenous contrast
agent was used in the proposed Cerenkov imaging method,
which opens great potentials for many exciting preclinical and
clinical applications.
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Fig. 4. Animal experiment #2: (a) tissue StO2 measured using the
proposed Cerenkov imaging method, (b) validation measurement at
the same ROIs on the animals using Zenalux oximeter, and (c) normal-
ized Cerenkov data versus Zenalux tissue StO2 data.
3104 Vol. 42, No. 16 / August 15 2017 / Optics Letters Letter
